Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Enliven Therapeutics Inc (ELVN)

Enliven Therapeutics Inc (ELVN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Enliven Therapeutics Inc 6200 Lookout Road Boulder CO 80301 USA

www.enliventherapeutics.com P: 720-647-8519

Description:

Enliven Therapeutics Inc. is a clinical-stage precision oncology company focused on the discovery and development of small molecule kinase inhibitors. The Company's lead product candidate includes ELVN-001 and ELVN-002. Enliven Therapeutics Inc., formerly known as Imara Inc., is based in Boulder, CO.

Key Statistics

Overview:

Market Capitalization, $K 1,083,732
Enterprise Value, $K 983,532
Shares Outstanding, K 47,037
Annual Sales, $ 0 K
Annual Net Income, $ -71,580 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -19,370 K
EBIT, $ -83,530 K
EBITDA, $ -87,840 K
60-Month Beta 1.05
% of Insider Shareholders 45.80%
% of Institutional Shareholders 95.08%
Float, K 25,494
% Float 54.20%
Short Volume Ratio 0.10

Growth:

1-Year Return 18.87%
3-Year Return -17.47%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.54 on 05/14/24
Next Earnings Date 05/16/24
Earnings Per Share ttm -2.19
EPS Growth vs. Prev Qtr -14.89%
EPS Growth vs. Prev Year 32.50%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-4 on 02/24/23

ELVN Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -28.83%
Return-on-Assets % -27.05%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 3.52
Book Value/Share 5.97
Interest Coverage -2.78
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar